References
- IDF Diabetes Atlas 10th edition. The International Diabetes Federation (IDF). URL:
https://diabetesatlas.org/data/en/ - Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Arch Intern Med. 2001;161:1989–1996.
- Maleki D, Locke GR, 3rd, Camilleri M, Zinsmeister AR,Yawn BP, Leibson C, Melton LJ, 3rd. Gastrointestinal tract symptoms among persons with diabetes mellitus in the community. Arch Intern Med. 2000;160:2808–2816.
- Camilleri M. Clinical practice. Diabetic gastroparesis. N Engl J Med. 2007;356:820–829.
- Intagliata N, Koch KL. Gastroparesis in type 2 diabetes mellitus: prevalence, etiology, diagnosis, and treatment. Curr Gastroenterol Rep. 2007;9:270–279.
- Zhao M, Liao D, Zhao J. Diabetes-induced mechanophysiological changes in the small intestine and colon. World J Diabetes. 2017;8(6):249–269.
- Horváth VJ, Putz Z, Izbéki F, Körei AE, Gerő L, Lengyel C, Kempler P, Várkonyi T. Diabetes-related dysfunction of the small intestine and the colon: focus on motility. Curr Diab Rep. 2015;15(11):94.
- Sellin JH, Hart R. Glucose malabsorption associated with rapid intestinal transit. Am J Gastroenterol. 1992;87:584–589.
- Rosa-e-Silva L, Troncon LE, Oliveira RB, Foss MC, Braga FJ, Gallo Júnior L. Rapid distal small bowel transit associated with sympathetic denervation in type I diabetes mellitus. Gut. 1996;39:748–756.
- Yarandi SS, Srinivasan S. Diabetic gastrointestinal motility disorders and the role of enteric nervous system: current status and future directions. Neurogastroenterol Motil. 2014;26:611–624.
- Imaeda K, Takano H, Koshita M, Yamamoto Y, Joh T, Suzuki H. Electrical properties of colonic smooth muscle in spontaneously non-insulin-dependent diabetic rats. J Smooth Muscle Res. 1998;34:1–11.
- Okamoto A, Yokokawa H, Nagamine T, Fukuda H, Hisaoka T, Naito T. Efficacy and safety of semaglutide in glycemic control, body weight management, lipid profiles and other biomarkers among obese type 2 diabetes patients initiated or switched to semaglutide from other GLP-1 receptor agonists. J Diabetes Metab Disord. 2021;20(2):2121–2128.
- Zheng C, Zhou M, Sun J, Xiong H, Peng P, Gu Z, Deng Y. The protective effects of Liraglutide on AD-like neurodegeneration induced by oxidative stress in human neuroblastoma SH-SY5Y cells. Chem Biol Interact. 2019;310:108688.
- He W, Wang H, Zhao C, Tian X, Li L, Wang H. Role of Liraglutide in brain repair promotion through Sirt1-mediated mitochondrial improvement in stroke. J Cell Physiol. 2020;235(3):2986–3001.
- Tiba AT, Qassam H, Hadi NR. Semaglutide in renal ischemia-reperfusion injury in mice. J Med Life. 2023;16(2):317–324
- Klein SR, Hobai IA. Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report. Can J Anaesth. 2023;70(8):1394–1396.
- Salles GN, Calió ML, Hölscher C, Pacheco-Soares C, Porcionatto M, Lobo AO. Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease. Neuropharmacology. 2020;162:107813.
- Takizawa Y, Oguri J, Uno M, Onsui A, Ishimura A, Kurita T, Nakajima T. Effects of a GLP-1 Receptor Agonist on Gastrointestinal Epithelial Cells. Sch Acad J Pharm. 2022;11(4):60–66.
- Overgaard RV, Navarria A, Ingwersen SH, Bækdal TA, Kildemoes RJ. Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials. Clin Pharmacokinet. 2021;60(10):1335–1348.
- Ozempic® Subcutaneous Injection 2mg Interview Form, Edition 5 (prepared May 2022)
- Trulicity® Subcutaneous Injection ATEOS® Interview Form, Edition 12 (prepared February 2023)
- Göke R, Conlon JM. Receptors for glucagon-like peptide-1(7–36) amide on rat insulinoma-derived cells. J Endocrinol. 1988;116:357–362.
- Brubaker PL, Drucker DJ. Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Recept Channels. 2002;8(3–4):179–188.
- Suzuki H. Analysis of xenobiotic detoxification system mediated by efflux transporters. Yakugaku Zasshi. 1999;119(11):822–834.
- Watanabe T, Maeda K, Nakai C, Sugiyama Y. Investigation of the effect of the uneven distribution of CYP3A4 and P-glycoprotein in the intestine on the barrier function against xenobiotics: a simulation study. J Pharm Sci. 2013;102(9):3196–3204.
- Canaparo R, Finnström N, Serpe L, Nordmark A, Muntoni E, Eandi M, Rane A, Zara GP. Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum. Clin Exp Pharmacol Physiol. 2007;34(11):1138–1144.
- Madara JL, Carlson S, Anderson JM. ZO-1 maintains its spatial distribution but dissociates from junctional fibrils during tight junction regulation. Am J Physiol. 1993;264(5 Pt 1):C1096–C1101.
- Chiou WL. Effect of ‘unstirred’ water layer in the intestine on the rate and extent of absorption after oral administration. Biopharm Drug Dispos. 1994;15(8):709–717.
- Zhang Z, Du Z, Liu Q, Wu T, Tang Q, Zhang J, Huang C, Huang Y, Li R, Li Y, Zhao Y, Zhang G, Zhou J, Huang H, Fang Z, He J. Glucagon-like peptide 1 analogue prevents cholesterol gallstone formation by modulating intestinal farnesoid X receptor activity. Metabolism. 2021;118:154728.
- Wang ZJ, Li XR, Chai SF, Li WR, Li S, Hou M, Li JL, Ye YC, Cai HY, Hölscher C, Wu MN. Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway. Neuropharmacology. 2023;240:109716
- Assessment report, Ozempic®. European Medicines Agency. EMA/CHMP/715701/2017
- Assessment report, Trulicity®. European Medicines Agency. EMA/CHMP/524604/2014
- Yao H, Gu J, Shan Y, Wang Y, Chen X, Sun D, Guo Y. Type 2 diabetes mellitus decreases systemic exposure of clopidogrel active metabolite through upregulation of P-glycoprotein in rats. Biochem Pharmacol. 2020;180:114142.
- Gwak EH, Yoo HY, Kim SH. Effects of Diabetes Mellitus on the Disposition of Tofacitinib, a Janus Kinase Inhibitor, in Rats. Biomol Ther (Seoul). 2020;28(4):361–369.
- Rehman AU, Siddiqui NZ, Farooqui NA, Alam G, Gul A, Ahmad B, Asim M, Khan AI, Xin Y, Zexu W, Song Ju H, Xin W, Lei S, Wang L. Morchella esculenta mushroom polysaccharide attenuates diabetes and modulates intestinal permeability and gut microbiota in a type 2 diabetic mice model. Front Nutr. 2022;9:984695.
- Lo Conte M, Cosorich I, Ferrarese R, Antonini Cencicchio M, Nobili A, Palmieri V, Massimino L, Lamparelli LA, Liang W, Riba M, Devecchi E, Bolla AM, Pedone E, Scavini M, Bosi E, Fasano A, Ungaro F, Diana J, Mancini N, Falcone M. Alterations of the intestinal mucus layer correlate with dysbiosis and immune dysregulation in human Type 1 Diabetes. EBioMedicine. 2023;91:104567.
- Eliuz Tipici B, Coskunpinar E, Altunkanat D, Cagatay P, Omer B, Palanduz S, Satman I, Aral F. Lactobacillus GG is associated with mucin genes expressions in type 2 diabetes mellitus: a randomized, placebo-controlled trial. Eur J Nutr. 2023;62(5):2155–2164.